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Abstract
IMPORTANCE—Studies document a progressive increase in heart disease risk as systolic blood 
pressure (SBP) rises above 115 mm Hg, but it is unknown whether an SBP lower than 120 mm Hg 
among adults with hypertension (HTN) lowers heart failure, stroke, and myocardial infarction risk.
OBJECTIVE—To examine the risk of incident cardiovascular (CV) events among adults with 
HTN according to 3 SBP levels: 140 mm Hg or higher; 120 to 139 mm Hg; and a reference level 
of lower than 120 mm Hg.
DESIGN, SETTING, AND PARTICIPANTS—A total of 4480 participants with HTN but 
without prevalent CV disease at baseline (years 1987–1989) from the Atherosclerosis Risk in 
Communities Study were included. Measurements of SBP were taken at baseline and at 3 triennial 
visits; SBP was treated as a time-dependent variable and categorized as elevated (≥140 mm Hg), 
standard (120–139 mm Hg), and low (<120 mm Hg). Multivariable Cox regression models 
included baseline age, sex, diabetes status, BMI, high cholesterol level, smoking status, and 
alcohol intake.
MAIN OUTCOMES AND MEASURES—Incident composite CV events (heart failure, ischemic 
stroke, myocardial infarction, or death related to coronary heart disease).
RESULTS—After a median follow-up of 21.8 years, a total of 1622 incident CV events had 
occurred. Participants with elevated SBP developed incident CV events at a significantly higher 
rate than those in the low BP group (adjusted hazard ratio [HR], 1.46; 95% CI, 1.26–1.69). 
However, there was no difference in incident CV event-free survival among those in the standard 
vs low SBP group (adjusted HR, 1.00; 95% CI, 0.85–1.17). Further adjustment for BP medication 
use or diastolic BP did not significantly affect the results.
CONCLUSIONS AND RELEVANCE—Among patients with HTN, having an elevated SBP 
carries the highest risk for cardiovascular events, but in this categorical analysis, once SBP was 
below 140 mm Hg, an SBP lower than 120 mm Hg did not appear to lessen the risk of incident CV 
events.
Elevated blood pressure (BP) is an important public health concern. It is highly prevalent 
and leads to several adverse cardiovascular outcomes, especially coronary heart disease 
(CHD), stroke, and heart failure (HF).1 Thus it is believed that even small improvements in 
the treatment of elevated BP would result in widespread cardiovascular benefit. The report 
to the Eighth Joint National Committee for Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC-8) recommends that individuals achieve a target systolic BP (SBP) 
<140 mm Hg and diastolic BP (DBP) lower than 90 mm Hg.2 The benefit of lowering SBP 
to around 140 mm Hg is well accepted, but patients treated to this level of BP may still be at 
increased risk of adverse cardiovascular outcomes. Observational studies document a 
progressive increase in heart disease risk as BP rises above 115/75 mm Hg.3,4 Such evidence 
suggests that there may be substantial benefit to targeting treatment to an SBP lower than 
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120 mm Hg instead of lower than 140 mm Hg, but whether an SBP lower than 120 mm Hg 
lowers cardiovascular event risk (such as HF, ischemic stroke, and CHD) is unknown.
The Atherosclerosis Risk in Communities (ARIC) Study5 prospectively collected data on 
incident cardiovascular events in a predominantly biracial cohort. In this context, we 
evaluate the relationship between SBP and the development of incident cardiovascular 
events such as myocardial infarction (MI), HF, ischemic stroke, and CHD death to address 
the question of what is the optimal BP range related to the lowest rate of incident 
cardiovascular events in participants with hypertension (HTN). We hypothesized that among 
participants with HTN (treated or untreated), cardiovascular event incidence would differ 
according to SBP levels, with an SBP of 140 mm Hg or higher or 120 to 139 mm Hg having 
an increased risk of incident cardiovascular events compared with an SBP lower than 120 
mm Hg. And because African Americans are at greater risk of HTN and HTN-related 
cardiovascular outcomes,6 we hypothesized that the this relationship would be more 
pronounced among African Americans.
Methods
The ARIC Study5 is an ongoing longitudinal cohort study designed to investigate the causes 
of atherosclerosis and cardiovascular disease. Detailed study rationale, design, and 
procedures have been previously published.5 The institutional review board at each 
participating institution approved the ARIC study, and all participants provided informed 
consent before each examination. At baseline (years 1987–1989), 15 792 men and women 
aged 45 to 64 years were enrolled in the study from 4 US communities: Forsyth County, 
North Carolina; Jack-son, Mississippi; suburban Minneapolis, Minnesota; and Washington 
County, Maryland. Subsequently, 3 follow-up examinations occurred at 3-year intervals 
after the baseline visit until the 1996–1998 follow-up. Telephone calls were made annually 
after enrollment to ascertain participant health status and any hospitalizations.
Trained study personnel and research technicians took all physical measurements and 
administered all questionnaires following a standardized protocol that included quality 
control measures. Technicians measured 3 seated BP readings after a 5-minute rest using 
random 0 sphygmomanometers. The average of the last 2 measures was used for analysis. 
Participants were requested to bring all their current medications during the field center 
visits. Interviewers inquired about whether the participants used medications for 
hypertension or diabetes, and the names of medications used in the past 2 weeks were 
transcribed from participants’ medication bottles. Body mass index (BMI) was calculated as 
weight in kilograms divided by height in meters squared. Diabetes mellitus was defined as 
having a fasting blood glucose level higher than 126 mg/dL, a non-fasting blood glucose 
level higher than 200 mg/dL, use of hypoglycemic medication, or a self-reported physician’s 
diagnosis. High cholesterol was defined as a total serum cholesterol higher than 240 mg/dL. 
Current smoking status (ever or never smoker) and alcohol drinking status (ever or never 
drinker) were self-reported. (To convert glucose to millimoles per liter, multiply by 0.0555; 
to convert cholesterol to millimoles per liter, multiply by 0.0259.)
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Of the original ARIC cohort study members, because of a small sample size, non–African 
Americans and nonwhites were excluded from this analysis (n = 35), as were African 
Americans who resided in Minneapolis or Washington County (n = 55). Only participants 
with HTN (defined as having an SBP >140 mm Hg and a DBP >90 mm Hg at baseline; 
having a self-reported history of physician-diagnosed HTN; or taking anti-hypertensive 
medication) were included in this analysis. Participants with missing baseline BP data were 
excluded from this analysis. Included participants were further categorized into 3 groups 
based on SBP level: Elevated SBP (≥140 mm Hg), Standard SBP (120–139 mm Hg), and 
Low SBP (<120 mm Hg) groups. Measurements of BP from the first screening visit 
(baseline) plus all 3 subsequent clinic visits spanning a period of 9 years were used to derive 
a time-dependent BP exposure variable for this study. Reclassification of participants into 
different BP categories based on subsequent clinic visits is detailed in eTable 1 in the 
Supplement.
Study Outcome Events
Our primary outcome was a composite of incident MI, CHD death, HF, and ischemic stroke. 
Each of these outcomes was also analyzed separately in secondary analysis. Incident MI or a 
CHD-related death was treated as a singular outcome (MI/CHD) throughout. Cardiovascular 
events were ascertained via annual telephone contacts with participants (or proxies) to 
identify all deaths and hospitalizations and by surveying discharge lists from local hospitals 
and death certificates from state vital statistics offices for potential cardiovascular events 
and recording of International Classification of Diseases, Ninth Revision (ICD-9) and/or 
International Classification of Diseases, Tenth Revision (ICD-10) codes from all hospital 
records occurring from baseline (1987–1989) through December 31, 2010.
Heart failure was defined as the first occurrence of either (1) an HF hospitalization that 
included an ICD-9 discharge code of 428 (428.0 to 428.9) in any position or (2) a death 
certificate with an ICD-9 code of 428 (HF) or an ICD-10 code of I50 (HF) in any position. 
The validity of this end point in ARIC has been documented.7 For ischemic stroke and MI/
CHD, hospital records were obtained and abstracted. All MI/CHD events were validated by 
a committee of physicians using standardized criteria.8 Incident strokes were validated by a 
combination of computerized algorithm and physician review.9 Participants were excluded 
from this analysis if they had a positive or unknown history of prevalent stroke and/or 
transient ischemic attack; unknown HF status or prevalent HF defined using the Gothenburg 
criterion10; or prevalent CHD determined by the presence of at least 1 of the following at the 
baseline visit: Q waves on the electrocardiogram, self-reported history of MI diagnosed by a 
physician, coronary artery bypass graft, or coronary angioplasty.
Statistical Analysis
To assess statistically significant differences of baseline demographic factors and key 
covariates across baseline SBP level categories, the Cochran-Armitage trend test was used 
for sex, diabetes, race, and high cholesterol level; the Kruskall-Wallis test for trend was used 
for cigarette and alcohol use; and the Spear-man ρ test for trend was used for age and BMI. 
In addition, P values comparing standard vs low and elevated vs low SBP groups were 
obtained by the χ2 test for categorical measures and Wilcoxon rank sum tests for continuous 
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measures. Incident rates (IRs) of hospitalized cardiovascular events were calculated by 
dividing the number of new HF, ischemic stroke, or MI/CHD cases in each SBP level 
category by the corresponding person-years. Incidence rate ratios (IRRs) were derived using 
the low BP group as the reference group. Poisson regression analysis was used to obtain 
age- and sex-adjusted IRs and IRRs. To assess the effect of SBP levels on HF, ischemic 
stroke, and MI/CHD incidence, survival analyses models using SBP as a time-dependent 
covariate were fit using BP measures from clinical examinations 1 through 4 over a period 
of more than years. Cox proportional hazards regression was used to estimate hazard ratios 
(HRs) and 95% CIs for the association between SBP level and incident cardiovascular 
events. Time to cardiovascular event was modeled in the presence of censoring. An 
individual was considered censored when he or she died from another cause or when the 
observation period ended. Models were fit for SBP as an ordinal variable with the inclusion 
for key covariates (baseline age, race, sex, diabetes, BMI, high cholesterol level, smoking 
status, and alcohol intake) to adjust for their effects. There was no significant violation of 
the proportional hazards assumption (P = .09) for the composite outcome (HF, ischemic 
stroke, or MI/CHD death) using the Wald linear hypothesis χ2 test. Standard Kaplan-Meier 
survival curves were generated for each baseline SBP category; the survival curves were 
compared with the use of the unadjusted log-rank test.
Additional analysis stratified our results according to race and sex to determine any race-sex 
differences. Formal tests for interaction were performed using interaction terms between 
race or sex and SBP category in age-adjusted models. We performed the following 
sensitivity analyses: (1) adjusting for antihypertensive treatment as a time-varying covariate; 
(2) adjusting for DBP as a time-varying covariate; (3) censoring cardiovascular event 
follow-up at the year 2000, since the BP control period for which we had data was for 9 
years following baseline, whereas follow-up for incident cardiovascular events was for 20 
years; and (4) comparing outcome events among those with an SBP from 140 to 159 mm Hg 
vs those with an SBP of 160 mm Hg or higher. Two-sided P values <.05 were considered 
significant. SAS software, version 9.3.4 (SAS Institute Inc) was used for all analyses.
Results
At baseline, the cohort of 4408 participants with HTN was relatively young, had a high 
prevalence of being overweight, and almost three-quarters were taking antihypertensive 
medication. Almost one-fifth of the cohort had diabetes, and two-thirds of the cohort had 
some smoking or alcohol history. High cholesterol level was prevalent in over 25% of the 
cohort. Table 1 summarizes participant baseline characteristics according to SBP level 
categories. Among this cohort of individuals with HTN, 43.7% had elevated SBP (≥140 mm 
Hg); 33.6% had standard SBP (120–139 mm Hg); and 22.7% had low SBP (<120 mm Hg). 
Within each category, and across both races, the proportions of participants taking 
antihypertensive medication at baseline were lowest among those with elevated SBP. 
Participants in the elevated SBP category tended to be older, were more likely to be male 
and African American, and were somewhat more likely to have diabetes.
After a median follow-up of 21.8 years, a total of 1622 incident composite cardiovascular 
events had occurred. The age-adjusted IR (AAIR) was lowest among adults with HTN in the 
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low SBP group and progressively higher in the higher SBP categories (Table 2 and Table 3). 
There were progressively higher IRRs in the elevated SBP group, particularly for those with 
SBPs higher than 160mm Hg, and in the standard SBP group compared with those in the 
low SBP group. White participants had significantly higher AAIRs in the elevated and 
standard SBP groups compared with those in the low SBP group. In men, women, and 
African Americans, once SBP levels were below 140 mm Hg, a progressively lower SBP 
was not associated with a lower AAIR of composite events. We found that African 
Americans had the highest absolute AAIR differential when comparing the highest SBP 
group (38.6 per 1000 person-years) vs the lowest (28.6 per 1000 person-years), which 
suggests that African Americans were more likely to have a greater absolute benefit of 
reduced cardiovascular events from achieving SBP levels below 140 mm Hg than any other 
group (Table 2 and Table 3). When evaluating each cardiovascular event outcome 
separately, we found that the elevated SBP group had a higher rate of HF, ischemic stroke, 
and MI/CHD events compared with the low SBP group. For HF events, the elevated SBP 
group had a significantly higher IRR than the low SBP group, but the IRR in the standard 
SBP group was not significantly different. This pattern was similar across race and sex 
groups. Is-chemic stroke and MI/CHD event IRRs did not appear to vary significantly by 
SBP category.
The unadjusted HRs of incident composite events were highest among those with elevated 
SBP (HR, 1.42; 95% CI, 1.23–1.65) compared with those in the low SBP group. The 
standard SBP group was not significantly different from the low SBP group in risk for 
incident cardiovascular events. This relationship remained unchanged after adjustments for 
age, sex, BMI, high cholesterol level, smoking status, alcohol intake, and diabetes. Cox 
proportional hazards models showed a 46% increased risk for incident composite events 
(HF, ischemic stroke, or MI/CHD) in the elevated SBP vs the low SBP group (HR, 1.46; 
95% CI, 1.26–1.69). There was no difference in incident cardiovascular event-free survival 
among those in the standard vs the low SBP groups (HR, 1.00; 95% CI, 0.85–1.17) (Figure 
1A). This pattern persisted when we evaluated HF, MI/CHD, and is-chemic stroke outcome 
events separately (Figure 1B–D). Unadjusted Kaplan-Meier curves (Figure 2A) illustrate 
worse cardiovascular event-free survival among participants with HTN in the highest SBP 
group compared with those in the lowest SBP group (log rank P < .001) and compared with 
those in the standard SBP group (log rank P = .01). However, this pattern did not persist 
when we looked at HF, MI/CHD, or ischemic stroke outcome events separately. The 
standard SBP group did not fare worse than the low SBP group (log rank P > .50) for any 
outcome (Figure 2B–D). In minimally and fully adjusted Cox proportional hazards models, 
the direct relationship between SBP level and incident composite events was similar for both 
men and women (P≥.50 for interaction). However, there was a significant effect by race (P 
= .02 for interaction), signaling a higher risk of cardiovascular events from elevated SBP 
among African Americans (HR, 1.66; 95% CI, 1.33–2.07) than among whites (HR, 1.26; 
95% CI, 1.04–1.54) (Figure 1). Further adjustment for BP medication use, DBP, or 
censoring cardiovascular event follow-up at year 2000 did not significantly affect the results 
(data not shown). Crude rates of MI/CHD, HF, or ischemic stroke stratified by SBP at 140 to 
159 mm Hg and 160 mm Hg or higher suggested an increase in incident cardiovascular 
events mostly in the 160 mm Hg or higher group (eTable 2 in the Supplement). This pattern 
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was not supported in multivariate models with SBP as a time-varying covariate, where 
significantly more composite events were seen in both the SBP 140 to 159 mm Hg and 160 
mm Hg or higher groups compared with the low SBP and the standard SBP groups (eFigure, 
A, in the Supplement).
Discussion
In this large, biracial, community-based cohort of men and women with HTN and long-term 
follow-up that addresses the time-varying nature of BP, we show that elevated BP among 
adults with HTN is an important risk factor for cardiovascular events (HF, stroke, and MI/
CHD) regardless of race and sex. We expected to see a significantly higher cardiovascular 
event-free survival among participants with HTN with progressively lower BP levels, but 
the relationship seen was not graded. Among participants with HTN, having elevated BP 
carries the highest risk for cardiovascular events, but in this categorical analysis we 
observed no overall risk difference between the standard (SBP, 120–139 mm Hg) and low 
(SBP, <120 mm Hg) SBP groups. Although our results reinforce that control of elevated BP 
is beneficial to prevent incident cardiovascular events, our results suggest that once SBP is 
controlled below 140 mm Hg, an SBP below 120 mm Hg does not appear to provide 
additional benefit in terms of preventing incident cardiovascular events. Furthermore, to our 
knowledge, this study provides the most information of this kind for African Americans, a 
population that manifests a heavy burden of HTN associated morbidity and mortality.11 Our 
results show that African Americans achieve a greater absolute benefit than whites in 
reduced incident cardiovascular events when elevated SBP is controlled.
According to a study of the NHANES population (National Health and Nutrition 
Examination Survey),12 nearly 20% of all hypertensive individuals in the United States are 
unaware of their condition, and more than 30% are not being treated. In addition, 49.9% of 
adults with high BP did not have their HTN controlled at the target of lower than <140 mm 
Hg as set out by JNC-7.12 This is due to many factors, including possible reluctance of 
physicians to achieve such goals, defined as clinical inertia, or perhaps lack of acceptance of 
aggressive therapy by patients as well.13,14
It should be noted that for the present study, the concept of control among adults with HTN 
was based solely on the participant’s BP, not on how much or what particular treatment they 
were undergoing. For example, the BP of some participants might have been controlled with 
lifestyle modifications alone or with only 1 medication, while others taking multiple 
medications or none at all might have had uncontrolled BP. Similarly, a person with an SBP 
of 140 mm Hg or higher is at increased cardiovascular risk whether taking antihypertensive 
medications or not, based simply on the BP. Nevertheless, our results do not support the 
notion that SBP control to lower than 120 mm Hg is better. Elevated BP is undoubtedly a 
risk factor for cardiovascular events, but standard BP control appears to be just as good as 
lower BP control in preventing HF, ischemic stroke, and MI/CHD. These results are 
potentially important, since treatment to a lower BP may have adverse consequences such as 
orthostatic hypotension, medication adverse effects, and increased health care costs.15,16
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A large meta-analysis of 61 cohort studies targeting 1 million participants including those 
with and without HTN demonstrated that cardiovascular morbidity and mortality decreased 
as the SBP decreased from 180 mm Hg to 115 mm Hg.3 Since then, the principle “the lower, 
the better” has been widely accepted. The contribution of elevated BP to the risk for 
developing cardiovascular events such as HF, MI, and stroke is substantial.17–20 Several 
clinical trials have demonstrated that treatment of an elevated SBP of 140 mm Hg or higher 
de creases the risk for cardiovascular events.21–27 However, although this evidence is very 
consistent for SBPs lower than 150 mm Hg, the benefit in preventing cardiovascular events 
among patients with HTN with SBPs lower than 120 mm Hg is unknown. Adequate control 
of elevated BP provides the earliest opportunity to prevent cardiovascular events.2,28 This 
notion is emphasized by the results of our study. However, the belief that intensifying 
antihypertensive treatment in patients with an SBP of 130 to 140 mm Hg offers any extra 
cardiovascular benefit has come into question.
To our knowledge no studies have assessed the incidence of HF, ischemic stroke, and 
MI/CHD with SBP control categories among a population-based cohort of patients with 
HTN. In the Framingham Heart Study,29 higher levels of BP were associated with risk of 
HF; however this study did not look exclusively at patients with HTN, did not categorize BP 
according to levels of BP control, and did not treat BP as a time-varying measure. The 
United Kingdom Prospective Diabetes Study30 compared tight BP control (<150/85 mm Hg) 
with less tight control (<180/105 mm Hg) in 1148 patients with HTN and diabetes. The 
group assigned to tight BP control had a 56% decreased risk of incident HF, a nonsignificant 
21% reduction in risk of MI, and a 44% reduction in risk of stroke compared with the group 
assigned to less tight BP control. The recent randomized controlled trial, the Action to 
Control Cardiovascular Risk in Diabetes,31 showed no significant difference in 
cardiovascular events between the intensive BP-lowering group, with a target SBP below 
120 mm Hg, and the standard treatment group, with a target SBP below 140 mm Hg. The 
recent JNC-8 report2 reinforces the 140/90 mm Hg or higher threshold for individuals 
younger than 60 years, citing a lack of evidence for increased cardiovascular risk at lower 
BP thresholds. Our results show that patients with HTN and SBPs below 120 mm Hg do not 
appear to have a lower risk of incident cardiovascular events than those with SBPs of 120 to 
139 mm Hg. Furthermore, some have suggested that mild hypertension (SBP, 140–159 mm 
Hg) does not confer significantly higher risk of cardiovascular events.32 However, our 
results show an increased risk for cardiovascular event for mild hypertension as well as for 
moderate to severe hypertension (SBP, >160 mm Hg). This also supports the JNC-8 
treatment threshold of an SBP of 140 mm Hg or higher.
One possible reason for our observed results is the so-called J-curve phenomenon, which 
describes a relationship between treatment to low BP levels and increased cardiovascular 
complications.33 Secondary analysis from recent large clinical outcomes trials have 
observed a J-curve effect between a DBP of 70 to 80 mm Hg as well as an SBP lower than 
130 mm Hg.34,35 This effect does not seem to appear in the absence of known obstructive 
CHD,33 presumably because the coronary arteries are perfused during diastole, but may be 
more pronounced in patients with HTN. However, the J-curve phenomenon remains 
controversial and has not been consistently shown. Examples are the Systolic Hypertension 
in the Elderly Program study36 and the Syst-Eur study,37 where no increase in myocardial 
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ischemia or cardiovascular disease risk was shown at a DBP of 55 to 60 mm Hg. According 
to the Cardiovascular Health Study38 the BP level and cardiovascular risk showed a linear 
relationship, and a J-curve was not observed. The Physicians’ Health Study and Women’s 
Health Study39 observed 22 071 men and 39 876 women for a median of 13.0 years and 6.2 
years, respectively, and found a linear association of SBP and DBP with the risk of MI, 
stroke, coronary artery bypass graft, angioplasty, and cardiovascular death without any 
evidence of a J-curve relationship.
Our study has some limitations. First, HF was based on hospital discharge ICD codes and 
not validated by physician review of medical records. Although HF diagnosis codes have 
been demonstrated to have high validity in ARIC,7 the true incidence of HF may be 
underestimated. Second, our study was observational, so despite a consistent statistical 
association, we cannot establish causality or account for unmeasured confounders not 
modeled in this study. We therefore await results from ongoing randomized clinical trials, 
such as the Systolic Blood Pressure Intervention Trial (SPRINT) sponsored by the National 
Heart, Lung, and Blood Institute (NHLBI), to help determine whether lowering SBP levels 
among patients with HTN has the potential to reduce cardiovascular events. Finally, the BP 
control period for which we had data was 9 years following baseline, whereas follow-up was 
for 20 years. It is likely that BP control for the final 11 years changed, and therefore some 
participants were misclassified prior to cardiovascular event diagnosis. However, our 
sensitivity analysis, ending follow-up at year 2000, showed similar results.
Conclusions
We show in a large, biracial, community-based cohort of un-selected individuals with HTN 
that those with an SBP lower than 120 mm Hg do not have reduced longitudinal risk of 
developing incident HF, ischemic stroke, or MI/CHD compared with individuals with HTN 
who have an SBP of 120 to 139 mm Hg. Thus, for controlling cardiovascular risk, a 
treatment goal of 120 to 139 mm Hg may be acceptable among most patients with HTN. 
Further studies are needed to support this conclusion, including the eventual results of the 
NHLBI SPRINT trial.
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Figure 1. Adjusted Hazard Ratios (HRs) of Incident Cardiovascular Events by Time-Varying 
Systolic Blood Pressure (SBP) Level Category Among Participants With Hypertension
The Atherosclerosis Risk in Communities Study5 (1987–2010) stratified by composite event 
(heart failure, ischemic stroke, or combination measure myocardial infarction/incidence of 
coronary heart disease death [MI/CHD]) (A), heart failure (B), ischemic stroke (C), and 
MI/CHD (D). Elevated BP is defined as an SBP of 140 mm Hg or higher; standard BP, an 
SBP of 120 to 139 mm Hg; and low BP, an SBP of lower than 120 mm Hg. The vertical 
lines through the HRs represent 95% CIs.
Rodriguez et al. Page 13













Figure 2. Unadjusted Cardiovascular Event-Free Survival Among Participants With 
Hypertension by Systolic Blood Pressure (SBP) Category
The Atherosclerosis Risk in Communities Study5 (1987–2010) stratified by composite event 
(heart failure, ischemic stroke, or combination measure myocardial infarction/incidence of 
coronary heart disease death [MI/CHD]) (A), heart failure (B), ischemic stroke (C), and 
MI/CHD (D). Elevated BP is defined as an SBP of 140 mm Hg or higher; standard BP, an 
SBP of 120 to 139 mm Hg; and low BP, an SBP of lower than 120 mm Hg.
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